BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 21, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN - News), a late-stage biopharmaceutical company focused on cardiovascular disease, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (R) (Nasdaq:NBI), which will become effective at the open of U.S. markets today.
